



ELSEVIER

# Inhibition by adenine dinucleotides of ATP-induced prostacyclin release by bovine aortic endothelial cells

Luminita H. Pojoga<sup>a,1</sup>, Maricela Haghia<sup>c</sup>, Richard H. Hilderman<sup>a,b,\*</sup>

<sup>a</sup>Department of Genetics and Biochemistry, Clemson University, Clemson, SC 29634-0324, USA

<sup>b</sup>The South Carolina Experiment Station, Clemson University, Clemson, SC 29634-0324, USA

Received 25 October 2001; accepted 5 February 2002

## Abstract

Adenine dinucleotides are a group of extracellular modulators involved in maintaining blood vessel tone. We have demonstrated previously that Ap<sub>2</sub>A and Ap<sub>4</sub>A induce the synthesis of both nitric oxide (NO) and prostacyclin (PGI<sub>2</sub>) in bovine aortic endothelial cells (BAEC), whereas Ap<sub>3</sub>A, Ap<sub>5</sub>A, and Ap<sub>6</sub>A do not. In this paper, we report that Ap<sub>2</sub>A and Ap<sub>4</sub>A are partial agonists for ATP in terms of Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis. The Ap<sub>4</sub>A EC<sub>50</sub> values for Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis were significantly higher than the corresponding values for ATP, while the Ap<sub>4</sub>A B<sub>max</sub> values for Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis were significantly lower than those for ATP. Ap<sub>2</sub>A and Ap<sub>4</sub>A concentration–effect curves for Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis demonstrated that Ap<sub>2</sub>A and Ap<sub>4</sub>A have antagonistic effects at ATP concentrations that induce responses above the maximal amount of Ca<sup>2+</sup> mobilized or PGI<sub>2</sub> synthesized by these two dinucleotides. On the other hand, Ap<sub>2</sub>A and Ap<sub>4</sub>A have agonistic effects at ATP concentrations that induce PGI<sub>2</sub> synthesis below the maximal amount of PGI<sub>2</sub> synthesized by these two dinucleotides. We also present evidence that suggests Ap<sub>3</sub>A, Ap<sub>5</sub>A, and Ap<sub>6</sub>A are antagonists for ATP in terms of PGI<sub>2</sub> synthesis. All these data are consistent with the adenine dinucleotides being negative modulators for ATP-induced PGI<sub>2</sub> synthesis.

© 2002 Elsevier Science Inc. All rights reserved.

**Keywords:** Ap<sub>x</sub>As; Ca<sup>2+</sup> mobilization; Prostacyclin; Endothelial cells

## 1. Introduction

Adenine dinucleotides represent a diverse and interesting group of extracellular mediators. These  $\alpha,\omega$ -adenine dinucleotides contain two adenosine moieties linked via their 5' positions by a chain of phosphates (Ap<sub>x</sub>A; x = 2–7). In the vascular system, Ap<sub>x</sub>As are co-stored with ATP in blood platelets and, upon platelet aggregation, are released into the extracellular milieu [1–3]. In the cardiovascular system, Ap<sub>x</sub>As have been shown to act as

vasoregulators, and to alter coronary resistance and cardiac electrophysiology [4].

Ap<sub>x</sub>As have been shown to exert various effects on vascular tone depending on the number of phosphate groups in the molecule. Whereas Ap<sub>2</sub>A, Ap<sub>3</sub>A, and Ap<sub>4</sub>A are vasodilators, Ap<sub>5</sub>A and Ap<sub>6</sub>A exhibit vasoconstrictive properties [5–10]. However, if the endothelium is removed from isolated arteries prior to infusion with Ap<sub>4</sub>A, then Ap<sub>4</sub>A interacts with VSMC to induce vasoconstriction [6,10]. Other investigators have shown that Ap<sub>x</sub>As (x = 4–6) significantly increase the [Ca<sup>2+</sup>]<sub>i</sub> in VSMC by interacting with VSMC purinoreceptors [11–14]. These observations suggest that the vasoactive response elicited by Ap<sub>x</sub>As may be determined by whether the dinucleotides interact directly with the endothelium to induce the release of vasoactive mediators or are internalized by the endothelium for trafficking to the basolateral membrane where they are released to interact with VSMC. An important and fundamental question is how are the Ap<sub>x</sub>As, which are released from the blood platelets simultaneously with other mono-

\* Corresponding author. Tel.: +1-864-656-3586; fax: +1-864-656-6879.

E-mail address: hilderr@clemson.edu (R.H. Hilderman).

<sup>1</sup>On leave from the Institute of Cellular Biology and Pathology “Nicolae Simionescu,” 8 B.P. Hasdeu Street, Bucharest 79691, Romania.

**Abbreviations:** 6-keto PGF<sub>1 $\alpha$</sub> , 6-keto prostaglandin F<sub>1 $\alpha$</sub> ; Ap<sub>x</sub>A, diadenosine polyphosphates; BAEC, bovine aortic endothelial cells; Bz-ATP, 3'-O-benzoyl-adenosine 5'-triphosphate; [Ca<sup>2+</sup>]<sub>i</sub>, intracellular calcium concentration; EIA, enzyme immunometric assay; FBS, fetal bovine serum; L-Arg, L-arginine; MEM, minimal essential medium; NO, nitric oxide; PGI<sub>2</sub>, prostacyclin; VSMC, vascular smooth muscle cells.

nucleotides, involved in maintaining vascular tone? Normal blood vessel tone appears to be maintained by a balanced constrictor–dilator interaction that is maintained by “cross-talk” among various vasoactive mediators synthesized by the endothelium [15–17]. The endothelium is a critical physiological target for maintaining blood vessel tone.

The biological effects on endothelial cells of adenine mononucleotides, but not the Ap<sub>x</sub>As, have been well characterized. ATP interacts with endothelial P<sub>2</sub> purinoreceptors to trigger Ca<sup>2+</sup> mobilization [18–25], and this Ca<sup>2+</sup> has been shown to be involved in the release of various vasoactive mediators such as NO and PGI<sub>2</sub> [18,26–28].

To characterize the interaction of Ap<sub>x</sub>As with the endothelium, our laboratory has demonstrated that Ap<sub>4</sub>A interacts with a heterogeneous population of receptors on BAEC [29]. The first binding site is a high-affinity site that is highly specific for Ap<sub>4</sub>A, Ap<sub>3</sub>A, and Ap<sub>2</sub>A. Nonradiolabeled Ap<sub>4</sub>A, Ap<sub>3</sub>A, and Ap<sub>2</sub>A were effective competitors of radiolabeled Ap<sub>4</sub>A binding, while Ap<sub>5</sub>A, Ap<sub>6</sub>A, and various P<sub>2</sub> purinoreceptor agonists and antagonists were not [29]. Competition binding studies also demonstrated that Ap<sub>4</sub>A binds with low affinity to a second class of binding sites [29]. Various P<sub>2</sub> purinoreceptor agonists and antagonists, along with Ap<sub>x</sub>As ( $x = 2–6$ ), effectively displace radiolabeled Ap<sub>4</sub>A from this low-affinity site [29]. We also demonstrated that Ap<sub>4</sub>A and Ap<sub>2</sub>A induce NO from BAEC, but Ap<sub>3</sub>A, Ap<sub>5</sub>A, and Ap<sub>6</sub>A do not [30]. In addition, we recently demonstrated that Ap<sub>4</sub>A and Ap<sub>2</sub>A enhance the selective uptake of L-Arg by BAEC and that this L-Arg is delivered to NO synthase for the generation of NO [31]. On the other hand, Ap<sub>3</sub>A, Ap<sub>5</sub>A, Ap<sub>6</sub>A, and Bz-ATP, a P<sub>2Z</sub> agonist, do not enhance the selective uptake of L-Arg [31]. Ap<sub>4</sub>A and Ap<sub>2</sub>A also induce Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis in BAEC, while Ap<sub>3</sub>A, Ap<sub>5</sub>A, and Ap<sub>6</sub>A induce Ca<sup>2+</sup> mobilization but not PGI<sub>2</sub> synthesis [32].

In this paper, we report that Ap<sub>4</sub>A and Ap<sub>2</sub>A induce PGI<sub>2</sub> synthesis by their interaction with low-affinity binding sites. Evidence is also presented that is consistent with Ap<sub>4</sub>A and Ap<sub>2</sub>A acting as partial agonists to ATP-induced Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis. These data suggest that Ap<sub>4</sub>A and Ap<sub>2</sub>A may act as modulators for ATP-induced PGI<sub>2</sub> synthesis.

## 2. Materials and methods

### 2.1. Materials

MEM was purchased from GIBCO. Adenine dinucleotides, ATP, suramin, penicillin, and streptomycin were purchased from the Sigma Chemical Co. Heat-inactivated FBS was purchased from HyClone. The 6-keto PGF<sub>1α</sub> acetylcholinesterase EIA Kit was purchased from the Cayman Chemical Co. Fluo-3/AM and Pluronic F-127 were purchased from Molecular Probes, Inc. All other reagents were of analytical grade or better.

### 2.2. Cell culture

BAEC were supplied by Dr. Robert Auerbach of the University of Wisconsin. Cells were grown in medium consisting of MEM, 10% (v/v) FBS, 44 mM NaHCO<sub>3</sub>, penicillin (100 units/mL), and streptomycin (100 µg/mL). Cell cultures were maintained at 37° in a humidified atmosphere of 95% air–5% CO<sub>2</sub>. All experiments were performed with passage 10 cells.

### 2.3. Fluo-3/AM loading of BAEC

BAEC were cultured in 100-cm<sup>2</sup> petri dishes as previously described [32] until they reached the early growth phase (2.5 to 5.0 × 10<sup>4</sup> cells/cm<sup>2</sup>). We have found that 1.5 mM probenecid effectively inhibits dye leakage from the cytosol (unpublished observations); therefore, all buffers and media used throughout the loading procedure and the fluorescence measurements contained 1.5 mM probenecid. To load the cells with Fluo-3, the plates were incubated with 400 nM Fluo-3/AM in cold MEM, supplemented with 10 µg/mL of BSA and 0.02% Pluronic F-127. Loading was performed for 1 hr in the following sequence: 15 min at room temperature, 15 min at 37°, followed by 30 min at room temperature. Incubations at room temperature were performed with continuous shaking. Plates were subsequently washed with MEM for 15 min at room temperature, and then allowed to recover at 37° for another 15 min in MEM supplemented with 10% FBS. Cells were isolated from plates by trypsinization, resuspended in MEM with 10% FBS, and then washed three times by centrifugation in Krebs-Henseleit buffer [10 mM HEPES (pH 7.4), 120 mM NaCl, 4.6 mM KCl, 1.5 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 1.5 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.7 mM Na<sub>2</sub>HPO<sub>4</sub>, and 10 mM glucose]. After resuspension in Krebs-Henseleit buffer, cell density was determined by using a hemacytometer. Cell suspensions with viability values of less than 85%, as determined by trypan blue exclusion, were discarded. Cell density was adjusted to 1.5 × 10<sup>6</sup> cells/mL with Krebs-Henseleit buffer, and a 2-mL aliquot of cell suspension was transferred to a cuvette for fluorescence measurements.

### 2.4. Fluorescence measurements and [Ca<sup>2+</sup>]<sub>i</sub> determination

Measurements were performed using an SLM 8000C Spectrofluorometer. The cuvette holder was connected to a magnetic stirrer so that cell suspensions were under continuous stirring conditions. The wavelengths used for excitation and emission were 504 and 526 nm, respectively (bandpass 4 nm). Typical fluorescence recordings are shown in Fig. 1. Following agonist stimulation, cells responded by a sharp and transient increase in the fluorescent signal, followed by a slow decay to basal levels. Calcium concentrations were calculated as described [33].




Fig. 1. Typical fluorescence tracings obtained by stimulating BAEC with ATP (A) or Ap<sub>4</sub>A (B). BAEC were loaded with Fluo-3/AM, resuspended in Krebs-Henseleit buffer ( $1.5 \times 10^6$  cells/mL), and transferred to the cuvette. After reading the basal level fluorescence, cells were challenged with 10  $\mu$ M ATP (A) or 1 mM Ap<sub>4</sub>A (B). After an initial peak, the fluorescent signal decayed to a level close to basal.

The dissociation constant was assumed to be 400 nM, previously determined at vertebrate ionic strength [33].

#### 2.5. Measurement of 6-keto PGF<sub>1 $\alpha$</sub> released by BAEC

The accumulation of 6-keto PGF<sub>1 $\alpha$</sub>  was used as an index of PGI<sub>2</sub> release. BAEC were grown in 96-well plates to confluence. Confluent monolayers were incubated overnight at 37° in serum-free MEM. The cells were then washed with Krebs-Henseleit buffer and resuspended in 300  $\mu$ L of Krebs-Henseleit buffer. To obtain a stable basal level of 6-keto PGF<sub>1 $\alpha$</sub> , the cells were incubated for 30 min at 37°, washed, resuspended in 300  $\mu$ L of Krebs-Henseleit buffer, and incubated for 30 min at 37°. This procedure was repeated three times. The cells were then resuspended in 300  $\mu$ L of Krebs-Henseleit buffer containing the adenine dinucleotides. The cells were incubated for 15 min at room temperature, and then aliquots were removed and diluted 100-fold with Krebs-Henseleit buffer for 6-keto PGF<sub>1 $\alpha$</sub>  assays. The amount of 6-keto PGF<sub>1 $\alpha$</sub>  was measured using the acetylcholinesterase immunoassay kit according to the specifications of the manufacturer.

#### 2.6. Statistical analysis

Normally distributed data from a minimum of eight experiments are reported as means  $\pm$  SEM. Student's two-tailed *t*-test was used to determine the statistical significance of a difference between means. A *P* value  $<0.05$  was considered to denote significance.

### 3. Results

#### 3.1. Effect of ATP and Ap<sub>4</sub>A on Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis in BAEC

Since ATP and Ap<sub>4</sub>A induce both Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis [18–28,32], we compared the effects of these two nucleotides on both Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis (Fig. 2 and Table 1).

To compare the effect of ATP and Ap<sub>4</sub>A on Ca<sup>2+</sup> mobilization, we measured [Ca<sup>2+</sup>]<sub>i</sub> transients in response to various concentrations of ATP and Ap<sub>4</sub>A. As shown in Fig. 2A, both ATP and Ap<sub>4</sub>A induced concentration-dependent Ca<sup>2+</sup> mobilization. However, the concentration–effect curve for Ap<sub>4</sub>A relative to ATP was shifted to the right. As shown in Table 1, the change in [Ca<sup>2+</sup>]<sub>i</sub> versus nucleotide concentration analyzed by nonlinear least-squares generated EC<sub>50</sub> values of 0.034 and 64.9  $\mu$ M for ATP and Ap<sub>4</sub>A, respectively, and  $\Delta[\text{Ca}^{2+}]_{\text{max}}$  values of 165 and 100 nM, respectively. Suramin (500  $\mu$ M), a nonselective P<sub>2</sub> purinoceptor antagonist, completely abolished Ap<sub>4</sub>A-induced Ca<sup>2+</sup> mobilization (data not shown). These data suggest that Ap<sub>4</sub>A interacts with P<sub>2</sub> purinoceptors to mobilize Ca<sup>2+</sup>.

To compare the effects of ATP and Ap<sub>4</sub>A on PGI<sub>2</sub> synthesis, BAEC were incubated for 15 min in the presence of various concentrations of ATP and Ap<sub>4</sub>A (Fig. 2B). As was the case with Ca<sup>2+</sup> mobilization, the Ap<sub>4</sub>A concentration–effect curve for PGI<sub>2</sub> synthesis was shifted to the right relative to ATP. The change in amount of PGI<sub>2</sub> synthesized versus nucleotide concentration analyzed by

Table 1  
Kinetic parameters of ATP- and Ap<sub>4</sub>A- induced Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis

Agonist	Calcium mobilization		PGI <sub>2</sub> release	
	EC <sub>50</sub> ( $\mu$ M)	$\Delta[\text{Ca}^{2+}]_{\text{max}}$ (nM)	EC <sub>50</sub> ( $\mu$ M)	$\Delta[6\text{-keto PGF}_{1\alpha}]_{\text{max}}$ (pg/10 <sup>5</sup> cells)
ATP	0.034 $\pm$ 0.01	165 $\pm$ 0.7	0.60 $\pm$ 0.06	2987 $\pm$ 57
Ap <sub>4</sub> A	64.90 $\pm$ 1.57	100 $\pm$ 0.6	60.1 $\pm$ 3.00	1324 $\pm$ 20

Experiments were performed as described in the legend of Fig. 2. Values are means  $\pm$  SEM, N  $\geq$  8.




Fig. 2. Effect of various concentrations of ATP and Ap<sub>4</sub>A on Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis in BAEC. (A) Fluo-3-loaded cells were suspended in Krebs-Henseleit buffer. After reading the baseline, the cells were challenged with the indicated concentrations of ATP or Ap<sub>4</sub>A. Calcium concentrations were determined as described under Section 2. Basal [Ca<sup>2+</sup>]<sub>i</sub> values were subtracted from ATP- and Ap<sub>4</sub>A-induced peak [Ca<sup>2+</sup>]<sub>i</sub> values. Data (means ± SEM) are from an average of at least eight different experiments. (B) BAEC were grown in gelatin-coated 96-well plates, and PGI<sub>2</sub> synthesis studies were performed as described under Section 2. BAEC were incubated at room temperature for 15 min in the presence of the indicated concentrations of ATP or Ap<sub>4</sub>A. Basal PGI<sub>2</sub> values were subtracted from Ap<sub>4</sub>A-induced PGI<sub>2</sub> synthesis values. Data (means ± SEM) are averages of three different experiments performed in triplicate.

nonlinear least-squares generated EC<sub>50</sub> values of 0.6 and 60.1 μM for ATP and Ap<sub>4</sub>A, respectively, and Δ[6-keto PGF<sub>1α</sub>]<sub>max</sub> values of 2987 and 1324 pg/10<sup>5</sup> cells, respectively. Both suramin (500 μM) and another nonspecific P<sub>2</sub> purinoceptor antagonist, Reactive Blue (10 μM), inhibited Ap<sub>4</sub>A-induced PGI<sub>2</sub> synthesis (data not shown). These data support the notion that Ap<sub>4</sub>A interacts with P<sub>2</sub> purinoceptors to induce the synthesis of PGI<sub>2</sub>.

### 3.2. Effect of various concentrations of Ap<sub>4</sub>A on ATP-induced Ca<sup>2+</sup> mobilization in BAEC

To determine whether Ap<sub>4</sub>A interacts with P<sub>2</sub> purinoceptors, the effect of Ap<sub>4</sub>A on ATP-induced Ca<sup>2+</sup> mobilization was examined. We measured [Ca<sup>2+</sup>]<sub>i</sub> transients in response to a fixed amount of ATP and various concentrations of Ap<sub>4</sub>A (Fig. 3). In the presence of 1 μM ATP (a concentration that induces maximal [Ca<sup>2+</sup>]<sub>i</sub> response), Ap<sub>4</sub>A had antagonistic effects, decreasing the ATP response to the level of the maximal Ap<sub>4</sub>A response (100 nM). The fact that the inhibition was not complete suggests that Ap<sub>4</sub>A may act as a partial agonist for the ATP response.

### 3.3. Effect of various concentrations of Ap<sub>4</sub>A on ATP-induced PGI<sub>2</sub> synthesis by BAEC

We determined the effect of Ap<sub>4</sub>A on ATP-induced PGI<sub>2</sub> synthesis. BAEC were incubated for 15 min in the presence or absence of fixed amounts of ATP and various concentrations of Ap<sub>4</sub>A. Fig. 4 shows a series of concentration-effect curves for Ap<sub>4</sub>A in the absence and in the presence of several different fixed concentrations of ATP. In the absence of ATP, Ap<sub>4</sub>A (1 mM) produced 48% of the maximal response generated by ATP. The effect of Ap<sub>4</sub>A in the presence of 0.1 and 1.0 μM ATP (ATP concentrations that produce responses less than the maximal response of Ap<sub>4</sub>A, i.e. 48%) was additive to those of ATP up to the maximal response of Ap<sub>4</sub>A. In contrast, Ap<sub>4</sub>A in the presence of 10 and 60 μM ATP (ATP concentrations that produce responses higher than the maximal response of Ap<sub>4</sub>A) had antagonistic effects, decreasing the response of ATP to the level of the maximal response of Ap<sub>4</sub>A. The increase in concentrations of Ap<sub>4</sub>A required to antagonize the effects of increasingly higher concentrations of ATP is indicative of the competitive nature of the




Fig. 3. Effect of various concentrations of Ap<sub>4</sub>A on ATP-induced Ca<sup>2+</sup> mobilization in BAEC. Experiments were performed as described in the legend of Fig. 2A using 1 μM ATP and the indicated concentrations of Ap<sub>4</sub>A. Basal [Ca<sup>2+</sup>]<sub>i</sub> values were subtracted from the agonist-induced peak [Ca<sup>2+</sup>]<sub>i</sub> values. Data (means ± SEM) were obtained from an average of at least eight different experiments.

effect. These data also support the notion that Ap<sub>4</sub>A is indeed a partial agonist for ATP [34].

#### 3.4. Effect of various concentrations of Ap<sub>2</sub>A on ATP-induced PGI<sub>2</sub> synthesis by BAEC

Since Ap<sub>2</sub>A also induces PGI<sub>2</sub> synthesis in BAEC [32], we determined the effect of Ap<sub>2</sub>A on ATP-induced PGI<sub>2</sub> synthesis. BAEC were incubated for 15 min in the presence of fixed amounts of ATP and various concentrations of Ap<sub>2</sub>A (Fig. 5). In the absence of ATP, 800 μM Ap<sub>2</sub>A

produced 62% of the maximal response of ATP. At 1 μM ATP, the effect of Ap<sub>2</sub>A was additive, but at 10 and 60 μM ATP the effect of Ap<sub>2</sub>A was antagonistic. These data are consistent with Ap<sub>2</sub>A acting as a partial agonist for ATP.

#### 3.5. Effect of other Ap<sub>x</sub>As on ATP-induced PGI<sub>2</sub> synthesis by BAEC

Ap<sub>3</sub>A, Ap<sub>5</sub>A, and Ap<sub>6</sub>A do not induce the release of PGI<sub>2</sub> from BAEC [32]. To determine whether these dinu-




Fig. 4. Effect of various concentrations of Ap<sub>4</sub>A on ATP-induced PGI<sub>2</sub> synthesis by BAEC. Experiments were performed as described in the legend of Fig. 2B using fixed concentrations of ATP and the indicated concentrations of Ap<sub>4</sub>A. Basal PGI<sub>2</sub> values were subtracted from agonist-induced PGI<sub>2</sub> synthesis values. Data (means ± SEM) are averages of at least three different experiments performed in triplicate.




Fig. 5. Effect of various concentrations of Ap<sub>2</sub>A on ATP-induced PGI<sub>2</sub> synthesis by BAEC. Experiments were performed as described in the legend of Fig. 2B using fixed concentrations of ATP and the indicated concentrations of Ap<sub>2</sub>A. Basal PGI<sub>2</sub> values were subtracted from agonist-induced PGI<sub>2</sub> synthesis values. Data (means  $\pm$  SEM) are averages of at least three different experiments performed in triplicate.

cleotides act as antagonists for ATP-induced PGI<sub>2</sub> synthesis, we measured ATP-induced PGI<sub>2</sub> synthesis in the presence and absence of the dinucleotides. BAEC were incubated for 15 min in the presence or absence of 500 μM Ap<sub>x</sub>A (a concentration that elicited maximal Ap<sub>2</sub>A and Ap<sub>4</sub>A responses) plus 60 μM ATP (a concentration that elicited maximal ATP response). As shown in Table 2, all three dinucleotides inhibited ATP-induced PGI<sub>2</sub> synthesis. Ap<sub>5</sub>A and Ap<sub>6</sub>A inhibited 43% of the maximal ATP response, while Ap<sub>3</sub>A inhibited 27%. These data are consistent with Ap<sub>3</sub>A, Ap<sub>5</sub>A, and Ap<sub>6</sub>A having an antagonistic effect on ATP-induced PGI<sub>2</sub> synthesis.

Table 2  
The effect of Ap<sub>x</sub>As on ATP-induced PGI<sub>2</sub> synthesis by BAEC

Nucleotide	6-keto PGF <sub>1α</sub> (pg/10 <sup>5</sup> cells)	P value	Relative percent
60 μM ATP	2650 $\pm$ 160		100
60 μM ATP plus 500 μM Ap <sub>3</sub> A	1940 $\pm$ 180	<0.05	73
60 μM ATP plus 500 μM Ap <sub>5</sub> A	1520 $\pm$ 190	<0.05	57
60 μM ATP plus 500 μM Ap <sub>6</sub> A	1510 $\pm$ 180	<0.05	57

Experiments were performed as described in the legend of Fig. 2B. Basal PGI<sub>2</sub> were subtracted from nucleotide-induced PGI<sub>2</sub> synthesis values. Data (means  $\pm$  SEM) were obtained from an average of three different experiments performed in triplicate.

#### 4. Discussion

The work presented in this paper arose from the observations that Ap<sub>2</sub>A and Ap<sub>4</sub>A mobilize Ca<sup>2+</sup> and induce the synthesis of PGI<sub>2</sub> in BAEC [32]. Our long-term goal is to characterize the interaction of Ap<sub>x</sub>As with endothelial cells, a critical physiological target. We have demonstrated previously that Ap<sub>4</sub>A interacts with a heterogeneous population of receptors on BAEC [29]. Ap<sub>4</sub>A binds with high affinity to a receptor that induces the release of NO [30,31], and it binds with low affinity to a second class of binding sites [29]. Competition binding studies using radiolabeled Ap<sub>4</sub>A and nonradiolabeled P<sub>2</sub> purinoceptor agonists and antagonists are consistent with the Ap<sub>4</sub>A low-affinity binding sites being P<sub>2</sub> purinoceptors [29]. The results reported herein are consistent with Ap<sub>2</sub>A and Ap<sub>4</sub>A acting as partial agonists for ATP-induced Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis from P<sub>2</sub> purinoceptors.

The EC<sub>50</sub> values obtained for Ap<sub>4</sub>A for Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis are significantly higher than the corresponding values obtained for ATP (Table 1). These data suggest that, when compared with ATP, Ap<sub>4</sub>A has a low affinity for the receptor system that induces Ca<sup>2+</sup> and PGI<sub>2</sub> synthesis. Furthermore, the ability of suramin/Reactive Blue to inhibit Ap<sub>4</sub>A-induced Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis (data not shown) was consistent with Ap<sub>4</sub>A inducing the synthesis of PGI<sub>2</sub> by interacting with one or more P<sub>2</sub> purinoceptor subtypes. Because of a lack of a generally accepted classification and of specific agonists

and antagonists, it is hard to identify the purinoceptor subtypes involved in the responses to ATP and Ap<sub>x</sub>As. However, in view of the fact that BAEC seem to be devoid of P<sub>2x</sub>-purinergic receptors, which within the cardiovascular system are preferentially located on cardiomyocytes and VSMC [35], it is conceivable that ATP and the Ap<sub>x</sub>As interact with P<sub>2y</sub> receptor subtypes. These receptors are found on the endothelium and mediate vasodilation through a G-protein-coupled system, unlike the P<sub>2x</sub> receptors, which are ligand-operated cation channels and mediate vasoconstriction on smooth muscle cells [35,36].

The B<sub>max</sub> values obtained for Ap<sub>4</sub>A for Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis are 1.6- and 2.2-fold lower, respectively, than the corresponding values obtained for ATP (Table 1). These data suggest that Ap<sub>4</sub>A induces Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis from a different receptor system than ATP or that Ap<sub>4</sub>A interacts with the same receptor system as ATP and is a partial agonist to ATP. Partial agonists by virtue of their occupation of a large number of receptors competitively block the effects of full agonists only at high concentrations of the full agonists. Since the effects of the partial agonist are the result of the interactions with the same site as the natural ligand, antagonism from partial agonists should be observed at the same concentrations that produce the agonist effect. Therefore, the agonistic response to a ligand that occurs at concentrations different than those that produce antagonism cannot be ascribed to interaction of the ligand with a single receptor. At ATP concentrations that induced PGI<sub>2</sub> synthesis above the maximal response elicited by Ap<sub>4</sub>A, Ap<sub>4</sub>A had an antagonistic effect up to the maximal Ap<sub>4</sub>A response (Fig. 4). On the other hand, at ATP concentrations that induced PGI<sub>2</sub> synthesis below the maximal response of Ap<sub>4</sub>A, Ap<sub>4</sub>A had an agonistic effect up to the level of the maximal Ap<sub>4</sub>A response. Similar concentration–effect curve experiments were performed using Ap<sub>2</sub>A and ATP (Fig. 5); the results were essentially the same as seen with Ap<sub>4</sub>A. These data are consistent with Ap<sub>2</sub>A and Ap<sub>4</sub>A being partial agonists for ATP. Alternatively, the agonistic effect seen in the presence of Ap<sub>4</sub>A may be due to a small ATP contamination (<1%). In this case, Ap<sub>4</sub>A would act as an antagonist instead of a partial agonist. Nevertheless, our data clearly demonstrate that Ap<sub>4</sub>A inhibits ATP-induced Ca<sup>2+</sup> mobilization and PGI<sub>2</sub> synthesis. Furthermore, we also demonstrated that Ap<sub>3</sub>A, Ap<sub>5</sub>A, and Ap<sub>6</sub>A inhibit ATP-induced PGI<sub>2</sub> synthesis (Table 2). These data are consistent with Ap<sub>x</sub>As inhibiting ATP-induced PGI<sub>2</sub> synthesis from P<sub>2</sub> purinoceptors. Other investigators, using clones of brain capillary endothelial P<sub>2y</sub> purinoceptors, have demonstrated that Ap<sub>4</sub>A and Ap<sub>5</sub>A also inhibit ADP-induced increases in [Ca<sup>2+</sup>]<sub>i</sub> [37]. In addition, Ap<sub>x</sub>As have been shown to induce Ca<sup>2+</sup> mobilization in different tissues via their interactions with various P<sub>2</sub> purinoceptor subtypes [6,11–15,32,37–42]. Thus, a fundamental and important question that needs to be addressed is whether the major physiological function for the interaction of

Ap<sub>x</sub>As with P<sub>2</sub> purinoceptors is to be a modulator of ATP signal transduction responses by acting as partial agonists or antagonists.

## Acknowledgments

This research was supported, in part, by NSF MCB-9816681, South Carolina Experiment Station Grant SC01630, and the Greenville Hospital System. The authors would like to thank Dr. Jim Zimmerman of Clemson University for critically evaluating the manuscript.

## References

- [1] Flodgaard H, Klenow H. Abundant amounts of diadenosine 5',5''-P<sup>1</sup>,P<sup>4</sup>-tetraphosphate are present and releasable, but metabolically inactive in human platelets. *Biochem J* 1982;208:737–42.
- [2] Schluter H, Offers E, Bruggean G, van der Giet M, Tepel M, Nordhoff E, Karas M, Spieker C, Witzel H, Zidek W. Diadenosine phosphates and the physiological control of blood pressure. *Nature* 1994;367:186–8.
- [3] Jankowski J, Potthoff W, van der Giet M, Tepel M, Zidek W, Schluter H. High-performance liquid chromatography assay for the diadenosine polyphosphates in human platelets. *Anal Biochem* 1999;269:72–8.
- [4] Flores NA, Stavrou BM, Sheridan DJ. The effects of diadenosine polyphosphates on the cardiovascular system. *Cardiovasc Res* 1999;42:15–22.
- [5] Pohl U, Ogilvie A, Lamontagne L, Busse R. Potent effects of Ap<sub>3</sub>A and Ap<sub>4</sub>A on coronary resistance and the autacoid release of intact rabbit hearts. *Am J Physiol* 1991;260:H1692–7.
- [6] Busse R, Ogilvie A, Pohl U. Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate. *Am J Physiol* 1988;254:H828–32.
- [7] Hilderman RH, Wist DB, Blackwell B, Hodgson EE, Swindle MM. The role of P<sup>1</sup>,P<sup>4</sup>-diadenosine 5'-tetraphosphate as a vasodilator. *Am J Hypertens* 1997;10:94A.
- [8] Kikuta Y, Sekine A, Tezuka S, Yamaura T, Nakajima H. Intravenous diadenosine tetraphosphate in dogs. *Acta Anaesthesiol Scand* 1994;38:284–8.
- [9] Ralevic V, Hoyle CHV, Burnstock G. Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. *J Physiol (Lond)* 1995;483:703–13.
- [10] van der Giet M, Khattab M, Borgel J, Schulter H, Zidek W. Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. *Br J Pharmacol* 1997;120:1453–60.
- [11] Verspohl EJ, Johannwille B, Kaiserling-Buddemeier I, Schlüter H, Hagemann J. Diadenosine polyphosphates in cultured vascular-smooth muscle cells and endothelium cells—their interaction with specific receptors and their degradation. *J Pharm Pharmacol* 1999;51:1175–81.
- [12] Tepel M, Bachmann J, Schulter H, Zidek W. Diadenosine polyphosphate-induced increase in cytosolic free calcium in vascular smooth muscle cells. *J Hypertens* 1995;13:1686–8.
- [13] Tepel M, Bachmann J, Schulter H, Zidek W. Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin II-induced change of calcium in vascular smooth muscle cells. *J Vasc Res* 1996;33:132–8.
- [14] Tepel M, Jankowski J, Schlüter H, Bachmann J, van der Giet M, Ruess C, Terliesner J, Zidek W. Diadenosine polyphosphates' action on calcium and vessel contraction. *Am J Hypertens* 1997;10:1404–10.

- [15] Warner TD. Relationships between the endothelium and nitric oxide pathways. *Clin Exp Pharmacol Physiol* 1999;26:242–52.
- [16] Warner TD. Characterization of endothelium synthetic pathways and receptor subtypes: physiological and pathophysiological implications. *Eur Heart J* 1993;14:42–7.
- [17] Boulanger CM, Luscher TF. Differential effect of cyclic GMP on the release of endothelin-1 from cultured endothelial cells. *J Cardiovasc Pharmacol* 1991;17:S264–6.
- [18] Carter TD, Hallam TJ, Cusack NJ, Pearson JD. Regulation of P<sub>2Y</sub>-purinoceptor-mediated prostacyclin release from human endothelial cells by cytoplasmic calcium concentration. *Br J Pharmacol* 1988;95:1181–90.
- [19] Pirotton S, Raspe E, Demolle D, Erneux C, Boeynaems JM. Involvement of inositol 1,4,5-trisphosphate and calcium in the action of adenine nucleotides on aortic endothelial cells. *J Biol Chem* 1987;262:17461–6.
- [20] Forsberg EJ, Feurestein G, Shoami E, Pollard HB. Adenosine triphosphate stimulates inositol phospholipid metabolism and prostacyclin formation in adrenal medullary endothelial cells by means of P<sub>2</sub>-purinergic receptors. *Proc Natl Acad Sci USA* 1987;84:5630–4.
- [21] Hallam TJ, Pearson JD. Exogenous ATP raises cytoplasmic free calcium in fura-2 loaded piglet aortic endothelial cells. *FEBS Lett* 1986;207:95–9.
- [22] Whorton AR, Willis CE, Kent RS, Young SL. The role of calcium in the regulation of prostacyclin synthesis by porcine aortic endothelial cells. *Lipids* 1984;19:17–24.
- [23] Luckoff A, Pohl U, Mulsch A, Busse R. Differential role of extra- and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. *Br J Pharmacol* 1988;95:189–96.
- [24] Hellewell PG, Pearson JD. Purinoceptor mediated stimulation of prostacyclin release in the porcine pulmonary vasculature. *Br J Pharmacol* 1984;83:457–62.
- [25] Janigro D, Nguyen TS, Gordon EL, Winn HR. Physiological properties of ATP-activated cation channels in rat brain microvascular endothelial cells. *Am J Physiol* 1996;270:H1423–34.
- [26] Cservatione RL, Smith JB, Hoak JC, Fry GL, Haycraft DC. Use of a radioimmunoassay to study thrombin-induced release of PGI<sub>2</sub> from cultured endothelium. *Thromb Res* 1979;14:781–6.
- [27] Brotherton AFA, Hoak JC. Role of Ca<sup>2+</sup> and cyclic AMP in the regulation of the production of prostacyclin by the vascular endothelium. *Proc Natl Acad Sci USA* 1982;79:495–9.
- [28] Seid JM, MacNeil S, Tomlinson S. Calcium calmodulin, and the production of prostacyclin by cultured vascular endothelial cells. *Biosci Rep* 1983;3:1007–15.
- [29] Campbell SA, Kemerling AJ, Hilderman RH. Characterization of P<sup>1</sup>,P<sup>4</sup>-diadenosine 5'-tetraphosphate binding on bovine aortic endothelial cells. *Arch Biochem Biophys* 1999;364:280–5.
- [30] Hilderman RH, Christensen EF. P<sup>1</sup>,P<sup>4</sup>-diadenosine 5' tetraphosphate induces nitric oxide release from bovine aortic endothelial cells. *FEBS Lett* 1998;427:320–4.
- [31] Cooper HM, Rosenberg CR, Hilderman RH. p<sup>1</sup>,p<sup>4</sup>-Diadenosine 5'-tetraphosphate induces the uptake of arginine and citrulline by a pore on the plasma membrane of bovine aortic endothelial cells. *FEBS Lett* 2000;485:57–61.
- [32] Haghia M, Pojoga LH, Hilderman RH. Studies on the effect of diadenylated nucleotides on calcium mobilization and prostacyclin synthesis in bovine aortic endothelial cells. *Cell Signal* 2001;13:145–50.
- [33] Kao JPY, Harootunian AT, Tsien RY. Photochemically generated cytosolic calcium pulses and their detection by fluo-3. *J Biol Chem* 1989;264:8179–84.
- [34] Mailman RB, Boyer J. [www.med.unc.edu/wrkunits/2depts/pharm/receptor/frame7](http://www.med.unc.edu/wrkunits/2depts/pharm/receptor/frame7)
- [35] Rongen GA, Floras JS, Lenders JWM, Thien T, Smits P. Cardiovascular pharmacology of purines. *Clin Sci* 1997;92:13–24.
- [36] Boarder MR, Hourani SMO. The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. *Trends Pharmacol Sci* 1998;19:99–107.
- [37] Vigne P, Breitmayer JP, Frelin C. Diadenosine polyphosphates as antagonists to the endogenous P2Y<sub>1</sub> receptor in rat brain capillary endothelial cells of B7 and B10 clones. *Br J Pharmacol* 2000;129:1506–12.
- [38] Hoyle CHV, Hilderman RH, Pintor JJ, Schluter H, King BF. Diadenosine polyphosphates as extracellular signal molecules. *Drug Dev Res* 2001;52:260–73.
- [39] Pintor J, Miras-Portugal MT. A novel receptor for diadenosine polyphosphates coupled to calcium increase in rat midbrain synaptosomes. *Br J Pharmacol* 1995;115:895–902.
- [40] Sen RP, Delicado EG, Castro F, Miras-Portugal MT. Effect of P<sub>2Y</sub> agonists on adenosine transport in cultured chromaffin cells. *J Neurochem* 1993;60:613–9.
- [41] Castro E, Tomé AR, Miras-Portugal MT, Rosário LM. Single-cell fura-2 microfluorometry reveals different purinoceptor subtypes coupled to Ca<sup>2+</sup> influx and intracellular Ca<sup>2+</sup> release in bovine adrenal chromaffin and endothelial cells. *Pflugers Arch* 1994;426:524–33.
- [42] Stachon A, Stegemann H, Hohage H, Rahn KH, Schlatter E. Effects of diadenosine polyphosphates on intracellular Ca<sup>2+</sup> concentration in endothelial cells. *Cell Physiol Biochem* 1998;8:175–84.